Peptide

Tesamorelin

Also known as

Egrifta · Egrifta SV · Egrifta WR · TH9507 · TH-9507 · Tesamorelin acetate · GHRH analog (trans-3-hexenoyl)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

GH-releasing peptide	Tesamorelin signals the pituitary to release growth hormone and raises IGF-1. It differs from injected HGH; community use is discussed by injection beneath the skin.
Deep belly fat	Visceral fat surrounds organs, unlike pinchable fat beneath the skin. Egrifta's HIV-lipodystrophy use is separate from general weight loss; a flatter belly does not prove internal-fat loss.

Notes

A growth-hormone signal. It mimics growth-hormone-releasing hormone, signaling the pituitary gland to release GH and raise IGF-1 throughout the body. It differs from injected HGH; subcutaneous means under the skin. Egrifta SV prescribing information (Official context · Accessed 2026-09-30)

Deep belly fat differs from pinchable fat. Visceral fat surrounds organs; subcutaneous fat sits beneath the skin. A flatter belly does not prove visceral-fat loss. Injection-site lumps are not local fat melting. Egrifta is approved for HIV-associated lipodystrophy, not general weight loss. Egrifta SV prescribing information (Official context · Accessed 2026-09-30) · No results on Tesamorelin (Community discussion · Accessed 2026-09-30)

Source context — Egrifta SV prescribing information: Finished branded formulation; human clinical population distinct from healthy biohackers or unidentified vials. Label revised February 2024. Recipe/storage instructions were not copied.

Source context — No results on Tesamorelin: Test-subject wording is required by this forum; identity/population unverified. 333 mcg is not 0.6 mg, so exact exposure cannot be reconstructed. No dose-response inference accepted.

What people notice

Midsection changes or no change	Some report a smaller-looking midsection with little scale movement; others see little physical or scale change after weeks or two months. Diet, lifting and other drugs often change too.
Sleep varies	One user reported better sleep in week one; others describe repeated waking, sore joints or fluid retention. Better sleep or higher IGF-1 alone does not show fat loss.

Notes

A smaller midsection without much scale movement. An ExcelMale contributor described 1 mg nightly, six nights/week, with changed diet and lifting. Weight barely changed. Their claimed internal-fat reduction was a visual interpretation, not documented imaging. Everything Tesamorelin — page 2 (Community discussion · Accessed 2026-09-30)

Midsection changes: weeks in some reports, none in others. A MESO user noticed a change around day 25 while changing anabolic-steroid use and taking MT2. In the retatrutide/tesamorelin log, the writer noticed little index movement for four to five weeks. A separate poster saw no physical or scale change after about two months. Loving my first go at tesamorelin (Community discussion · Accessed 2026-09-30) · Data trends during my Tesamorelin cycle (Community discussion · Accessed 2026-09-30) · No results on Tesamorelin (Community discussion · Accessed 2026-09-30)

Tesamorelin is an injectable peptide that prompts the body to release growth hormone. Biohackers discuss it for stubborn deep abdominal fat, body recomposition and sleep. Reports range from a smaller-looking midsection or better rest to little visible change, disrupted sleep, fluid retention and itchy reactions.

Sleep and recovery are separate outcomes. An ASF contributor described better sleep in week one at 1 mg pre-bed. Others wake repeatedly or feel sore. Recovery and lean retention are also sought; better sleep or IGF-1 alone cannot demonstrate fat loss. Tesamoralin Dosing (Personal report · Accessed 2026-09-30) · Tesamorelin Sleep Disturbances (Community discussion · Accessed 2026-09-30)

Source context — Everything Tesamorelin — page 2: Claims of visible VAT loss and 15–18% estimates were not imaging-proven. Food explanation is speculation. Repeated quotes on the page count as one account, not independent corroboration.

Source context — Loving my first go at tesamorelin: Only opened page 1, not all nine pages. Mixed advice, clinical repetition and first-person reports; measured VAT loss, safety assurances, mechanistic certainty and superior-stack claims not accepted.

Source context — Data trends during my Tesamorelin cycle: Author does not supply raw longitudinal data or pre/post imaging results. Smart-scale index is an algorithmic estimate; AI analysis of private data and water explanation unvalidated. No attribution to tesamorelin alone.

Source context — Tesamoralin Dosing: One unverified self-report amid bodybuilding discussion. The route is not specified in the quoted experience; optimistic prediction of faster outcomes not accepted.

Source context — Tesamorelin Sleep Disturbances: Selected anonymous accounts, not prevalence or causation. Dose frequency unclear in some replies; fifth-night user's stated .5/week is ambiguous and not converted.

Doses people talk about

Community 1–2 mg	Saved talk centers on 1–2 mg per SubQ administration, often daily. One log used 2 mg nightly five nights/week; 1-to-2 mg changes are tolerance/cost lore, not a proven escalation plan.
Lower amounts	Roughly 0.25 mg and 0.3 mg also appear with poor sleep. A separate 0.5-to-1-to-2 mg course omits daily frequency; milligrams are not syringe units.
Branded products differ	Original trials used 2 mg daily; SV uses 1.4 mg and WR 1.28 mg daily with comparable exposure to the original product. SV, WR and unverified community vials are not interchangeable.

Notes

1–2 mg per administration, often once daily, by subcutaneous injection. The original discussion includes 1 mg/day for 1–2 weeks then 2 mg as tolerance/cost lore. An opened log used 2 mg nightly five nights/week. These are reports, not an escalation plan or proven Egrifta equivalence. Data trends during my Tesamorelin cycle (Community discussion · Accessed 2026-09-30)

Lower amounts also appear; smaller does not mean symptom-free. Reports include roughly 0.25 mg or 0.3 mg with poor sleep. One ten-week injection account progressed from 0.5 to 1 to 2 mg, then used 1 mg on a later course; its daily frequency was unstated. Milligrams are not interchangeable with syringe 'units'. Tesamorelin Sleep Disturbances (Community discussion · Accessed 2026-09-30) · Tesamorelin Experience (Community discussion · Accessed 2026-09-30)

Branded amounts belong to specific products. Original trials used 2 mg SC daily. SV uses 1.4 mg daily; WR uses 1.28 mg daily, with exposure comparable to the original product. SV and WR are not substitutable; community vials are not proven equivalents. Egrifta SV prescribing information (Official context · Accessed 2026-09-30) · Egrifta WR prescribing information (Official context · Accessed 2026-09-30)

Source context — Tesamorelin Experience: Frequency not explicit for OP; route described as injection but products unverified. OP reports hospital did not classify event as anaphylaxis. Positive responder also includes sourcing/promotion, excluded from article.

Source context — Egrifta WR prescribing information: WR finished product only, not blend/RUO equivalence or off-label efficacy. No preparation instructions or storage recipe reproduced.

Half-life, onset & duration

Felt onset	Sleep changes are reported in the first nights or week. Some midsection reports begin around day 25.
Felt duration	No dependable single-dose sleep or recovery window emerges. Poor sleep over seven weeks describes continued use; off-day scale drops do not establish a fat-loss or washout clock.
Half-life	Saved labels give single-SubQ-dose means of 8 minutes for SV and 11 for WR in healthy subjects. Older HIV data give 18 minutes single-dose and 37 repeated-dose; the forum's 30 minutes is separate lore.

Notes

Sleep changes can begin in the first nights. Accounts describe repeated waking from nights one and two; the ASF user reported better sleep during week one. The original record also describes little acute 'buzz'. These are different experiences, not a predictable onset clock. Tesamorelin Sleep Disturbances (Community discussion · Accessed 2026-09-30) · Tesamoralin Dosing (Personal report · Accessed 2026-09-30)

No dependable single-dose benefit window. The reports do not establish a number of hours for sleep or recovery benefits. Seven weeks of poor sleep with sore joints describes symptoms during continued use, not one injection lasting seven weeks. Tesamorelin Sleep Disturbances (Community discussion · Accessed 2026-09-30)

Water can obscure weight trends during a course. The five-night log describes larger scale drops on off days and attributes that pattern to fluid retention. Raw data were not supplied. This does not show that fat loss starts only after stopping, or establish a washout time. Data trends during my Tesamorelin cycle (Community discussion · Accessed 2026-09-30)

About 30 minutes is a repeated forum estimate. A MESO contributor repeats this figure while debating GH pulses; they did not measure clearance or identify the underlying formulation. It is circulated pharmacology, not a user-measured effect window. Loving my first go at tesamorelin (Community discussion · Accessed 2026-09-30)

Eight minutes also circulates, with a label origin. The USPeptides guide repeats a figure matching Egrifta SV's single-dose label measurement. It is not independent community kinetics. Neither number tells how long sleep changes, water retention or body-composition effects last. Tesamorelin Dosing: 1mg vs 2mg, 5-on-2-off vs Daily, and Micro-Dosing (Community guide · Accessed 2026-09-30)

Measured blood half-life: SV 8 minutes; WR 11 minutes. These are single-SC-dose means in healthy subjects, with median blood peak around nine minutes. The older FDA review gives 18 minutes single-dose and 37 minutes repeated-dose in HIV subjects. These formulation/population contexts aren't interchangeable. Egrifta SV prescribing information (Official context · Accessed 2026-09-30) · Egrifta WR prescribing information (Official context · Accessed 2026-09-30) · FDA Egrifta clinical pharmacology review, original NDA (Official context · Accessed 2026-09-30)

Source context — Tesamorelin Dosing: 1mg vs 2mg, 5-on-2-off vs Daily, and Micro-Dosing: Guide includes commercial/sourcing language and mixing recipes, not reproduced. Its formal PK repetition is not user-measured half-life. Advice, 'irrelevant' night side effects and permanent-results claim rejected. Lab figures self-reported.

Source context — Egrifta WR prescribing information: WR finished product only, not blend/RUO equivalence or off-label efficacy. No preparation instructions or storage recipe reproduced.

Source context — FDA Egrifta clinical pharmacology review, original NDA: Historical formulation, populations and assay conditions. Extracted text inspected; tables not used to build a pooled universal range. No community human measurement.

Cycles people discuss

8–16-week community runs	Opened accounts include ten and twelve weeks, five-on/two-off or six-on/one-off. Vial arithmetic and lifestyle help explain these patterns; validated receptor rest does not.
Longer courses and breaks	Clinic marketing describes 3–6 months or three months on/1–2 off. Cost, swelling, joints and lab changes prompt other pauses; no standard break or PCT emerges.

Notes

Eight to sixteen weeks; five-on/two-off and six-on/one-off. The original community record includes 8–16-week cuts; opened accounts include 10- and 12-week courses. The five-night log chose its rhythm partly for vial arithmetic, while an ExcelMale user described six nights/week. These schedules are not validated 'receptor rest'. Tesamorelin Experience (Community discussion · Accessed 2026-09-30) · Data trends during my Tesamorelin cycle (Community discussion · Accessed 2026-09-30) · Everything Tesamorelin — page 2 (Community discussion · Accessed 2026-09-30)

Longer courses and breaks vary. Preserved clinic marketing describes 3–6 months, sometimes three months on then 1–2 months off. People also pause for cost, swelling, joint symptoms or abnormal labs. One commenter stopped four weeks after high reported IGF-1/insulin. No standard break or post-cycle therapy emerges. Tesamorelin Dosing: 1mg vs 2mg, 5-on-2-off vs Daily, and Micro-Dosing (Community guide · Accessed 2026-09-30)

Stacks

GH-axis combinations	Ipamorelin, CJC/Mod GRF and sermorelin appear in stack talk. Dual-GHRH or HGH layering is debated as redundant; it does not establish an equivalent dose or safe swap.
Fat-loss and recovery stacks	Retatrutide, semaglutide/tirzepatide, MOTS-c and BPC/TB combinations appear. Favorable changes cannot be assigned to tesamorelin alone or establish tested compatibility.

Notes

Stack results cannot isolate Tesamorelin. Retatrutide co-use complicates the weight log. The old discussion also includes semaglutide/tirzepatide, ipamorelin, CJC/Mod GRF, sermorelin, MOTS-c and BPC/TB recovery combinations. These are different drugs and goals; a favorable combination is not tested compatibility. Data trends during my Tesamorelin cycle (Community discussion · Accessed 2026-09-30)

GH-axis alternatives have different tradeoffs. Preserved comparisons contrast tesa's visceral-fat interest with sermorelin's sleep/longevity framing, longer CJC-with-DAC claims, MK-677 hunger/water talk and direct HGH. Dual-GHRH or HGH layering is debated as redundant; no equivalent dose or safe swap follows.

Tesamorelin + Ipamorelin: Most common dual-pathway stack talk — GHRH analog + selective GHRP/ghrelin-receptor agonist for a bigger GH pulse; confounds credit and may amplify water/joint/IGF-1 sides. [community]

Tesamorelin + CJC-1295 / Mod GRF + Ipamorelin: “Full GH-axis” layering in wellness clinics; some providers position tesa for VAT and CJC/Ipa for recovery/sleep — heavy confounding and higher side risk. [community]

Tesamorelin + sermorelin: Minority “two GHRH” talk (e.g., tesa AM / sermorelin bedtime lore); other clinicians call dual GHRH non-standard and riskier for supraphysiologic GH/IGF-1. [community]

+ GLP-1 / dual / triple agonists: Frequently stacked with semaglutide, tirzepatide, or retatrutide in fat-loss forums — reta/sema drive appetite and total fat while tesa is sold as VAT polish; highly confounded. [community]

+ MOTS-c: Appears in “metabolic stack” cheat sheets with reta + tesa; preclinical/community adjacency more than a joint RCT. [community]

+ healing peptides (BPC-157 / TB-500): Occasional recovery stacks when joint comfort is already an issue on GH-axis drugs — separate mechanisms, anecdote-level. [community]

Watch for

Itch and wider reactions	One later course brought hives, lip/tongue tingling and unusual swallowing within 5–10 minutes, prompting ER care. The cause was unknown; swallowing or breathing difficulty needs urgent care.
Fluid, joints and glucose	Reports include puffiness, tingling and sore joints. Labels warn about fluid retention, carpal-tunnel symptoms and glucose intolerance, and call for IGF-1/glucose assessment.
Contraindications and sport	Label contraindications include active malignancy, pregnancy, disrupted pituitary signaling and hypersensitivity. The saved sport list prohibits tesamorelin; half-life is not a clearance interval.

Notes

Itchy lumps can precede a wider reaction. The later 1 mg course brought hives, lip/tongue tingling and odd swallowing within 5–10 minutes, prompting ER care. The hospital reportedly did not call it anaphylaxis. Cause unknown; swallowing or breathing difficulty requires urgent care. Tesamorelin Experience (Community discussion · Accessed 2026-09-30) · Egrifta WR prescribing information (Official context · Accessed 2026-09-30)

Puffiness, tingling and sore joints are meaningful tradeoffs. One commenter reported fewer symptoms changing 2 mg to 1 mg; another had sore joints through seven weeks. Labels warn about fluid retention, carpal-tunnel symptoms and glucose intolerance. Less discomfort does not establish safety. Tesamorelin Dosing: 1mg vs 2mg, 5-on-2-off vs Daily, and Micro-Dosing (Community guide · Accessed 2026-09-30) · Tesamorelin Sleep Disturbances (Community discussion · Accessed 2026-09-30) · Egrifta WR prescribing information (Official context · Accessed 2026-09-30)

Cancer, pregnancy and pituitary conditions matter. Labeling contraindicates active malignancy, pregnancy, disrupted pituitary signaling and known hypersensitivity. It calls for IGF-1/glucose assessment and warns about diabetes-related retinopathy. Combining products does not remove these cautions. Egrifta WR prescribing information (Official context · Accessed 2026-09-30)

Tested sport has a separate boundary. WADA's 2026 list prohibits tesamorelin at all times. Forum half-life figures cannot supply an anti-doping clearance interval. WADA 2026 Prohibited List (Official context · Accessed 2026-09-30)

Source context — Egrifta WR prescribing information: WR finished product only, not blend/RUO equivalence or off-label efficacy. No preparation instructions or storage recipe reproduced.

Source context — WADA 2026 Prohibited List: Eligibility context only, not a detection or washout calculator. Applicable anti-doping rules and exemptions remain separate.

Full notes

What Tesamorelin is

A growth-hormone signal. It mimics growth-hormone-releasing hormone, signaling the pituitary gland to release GH and raise IGF-1 throughout the body. It differs from injected HGH; subcutaneous means under the skin. Official context Community
Deep belly fat differs from pinchable fat. Visceral fat surrounds organs; subcutaneous fat sits beneath the skin. A flatter belly does not prove visceral-fat loss. Injection-site lumps are not local fat melting. Egrifta is approved for HIV-associated lipodystrophy, not general weight loss. Official context Reddit r/PeptidePathways Community

What people hope to notice

A smaller midsection without much scale movement. An ExcelMale contributor described 1 mg nightly, six nights/week, with changed diet and lifting. Weight barely changed. Their claimed internal-fat reduction was a visual interpretation, not documented imaging. ExcelMale
Sleep and recovery are separate outcomes. An ASF contributor described better sleep in week one at 1 mg pre-bed. Others wake repeatedly or feel sore. Recovery and lean retention are also sought; better sleep or IGF-1 alone cannot demonstrate fat loss. Personal report Reddit r/Biohackers Community

Doses people discuss

1–2 mg per administration, often once daily, by subcutaneous injection. The original discussion includes 1 mg/day for 1–2 weeks then 2 mg as tolerance/cost lore. An opened log used 2 mg nightly five nights/week. These are reports, not an escalation plan or proven Egrifta equivalence. Community Reddit r/BodyHackGuide
Lower amounts also appear; smaller does not mean symptom-free. Reports include roughly 0.25 mg or 0.3 mg with poor sleep. One ten-week injection account progressed from 0.5 to 1 to 2 mg, then used 1 mg on a later course; its daily frequency was unstated. Milligrams are not interchangeable with syringe 'units'. Reddit r/Biohackers Reddit r/Biohackers

Half-life discussed in the community

About 30 minutes is a repeated forum estimate. A MESO contributor repeats this figure while debating GH pulses; they did not measure clearance or identify the underlying formulation. It is circulated pharmacology, not a user-measured effect window. MESO-Rx
Eight minutes also circulates, with a label origin. The USPeptides guide repeats a figure matching Egrifta SV's single-dose label measurement. It is not independent community kinetics. Neither number tells how long sleep changes, water retention or body-composition effects last. Community guide

When people notice changes

Sleep changes can begin in the first nights. Accounts describe repeated waking from nights one and two; the ASF user reported better sleep during week one. The original record also describes little acute 'buzz'. These are different experiences, not a predictable onset clock. Reddit r/Biohackers Personal report Community
Midsection changes: weeks in some reports, none in others. A MESO user noticed a change around day 25 while changing anabolic-steroid use and taking MT2. In the retatrutide/tesamorelin log, the writer noticed little index movement for four to five weeks. A separate poster saw no physical or scale change after about two months. MESO-Rx Reddit r/BodyHackGuide Reddit r/PeptidePathways

How long effects are reported to last

No dependable single-dose benefit window. The reports do not establish a number of hours for sleep or recovery benefits. Seven weeks of poor sleep with sore joints describes symptoms during continued use, not one injection lasting seven weeks. Reddit r/Biohackers
Water can obscure weight trends during a course. The five-night log describes larger scale drops on off days and attributes that pattern to fluid retention. Raw data were not supplied. This does not show that fat loss starts only after stopping, or establish a washout time. Reddit r/BodyHackGuide

Courses and breaks people describe

Eight to sixteen weeks; five-on/two-off and six-on/one-off. The original community record includes 8–16-week cuts; opened accounts include 10- and 12-week courses. The five-night log chose its rhythm partly for vial arithmetic, while an ExcelMale user described six nights/week. These schedules are not validated 'receptor rest'. Community Reddit r/Biohackers Reddit r/BodyHackGuide ExcelMale
Longer courses and breaks vary. Preserved clinic marketing describes 3–6 months, sometimes three months on then 1–2 months off. People also pause for cost, swelling, joint symptoms or abnormal labs. One commenter stopped four weeks after high reported IGF-1/insulin. No standard break or post-cycle therapy emerges. Community Community guide

Watch for

Itchy lumps can precede a wider reaction. The later 1 mg course brought hives, lip/tongue tingling and odd swallowing within 5–10 minutes, prompting ER care. The hospital reportedly did not call it anaphylaxis. Cause unknown; swallowing or breathing difficulty requires urgent care. Reddit r/Biohackers Official context
Puffiness, tingling and sore joints are meaningful tradeoffs. One commenter reported fewer symptoms changing 2 mg to 1 mg; another had sore joints through seven weeks. Labels warn about fluid retention, carpal-tunnel symptoms and glucose intolerance. Less discomfort does not establish safety. Community guide Reddit r/Biohackers Official context
Cancer, pregnancy and pituitary conditions matter. Labeling contraindicates active malignancy, pregnancy, disrupted pituitary signaling and known hypersensitivity. It calls for IGF-1/glucose assessment and warns about diabetes-related retinopathy. Combining products does not remove these cautions. Official context Community
Tested sport has a separate boundary. WADA's 2026 list prohibits tesamorelin at all times. Forum half-life figures cannot supply an anti-doping clearance interval. Official context

What formal evidence actually describes

Branded amounts belong to specific products. Original trials used 2 mg SC daily. SV uses 1.4 mg daily; WR uses 1.28 mg daily, with exposure comparable to the original product. SV and WR are not substitutable; community vials are not proven equivalents. Official context Official context
Measured blood half-life: SV 8 minutes; WR 11 minutes. These are single-SC-dose means in healthy subjects, with median blood peak around nine minutes. The older FDA review gives 18 minutes single-dose and 37 minutes repeated-dose in HIV subjects. These formulation/population contexts aren't interchangeable. Official context Official context Official context
Study timelines are months, with rebound after withdrawal. HIV trials assessed visceral fat at 26 weeks, then continued or withdrew treatment through 52 weeks. Withdrawal groups regained visceral fat. That does not promise a healthy athlete's result or permanent change. Official context
Liver fat is a separate research endpoint. Stanley et al.'s HIV/NAFLD trial used 2 mg daily for 12 months and found a liver-fat difference of 4.1 percentage points versus placebo, about 37% relative reduction from baseline. This is not a community 'cut' estimate. Official context

What community experience adds

Meal timing competes with sleep and everyday life. The old discussion describes roughly two hours after food and 30–90 minutes before bed; other accounts use mornings. These are GH-pulse/insulin rationales, not verified tesamorelin outcome rules. An ExcelMale reply even suggested fasting itself might worsen sleep. Community ExcelMale
Wearables and mirrors can disagree with the person. One 0.5 mg nightly user felt worse sleep while their watch looked better. A six-week user saw no change in a smart-scale visceral-fat index despite a visual improvement. Neither tracker scores nor a mirror establish measured internal fat loss. Reddit r/Biohackers Reddit r/BodyHackGuide
Stack results cannot isolate Tesamorelin. Retatrutide co-use complicates the weight log. The old discussion also includes semaglutide/tirzepatide, ipamorelin, CJC/Mod GRF, sermorelin, MOTS-c and BPC/TB recovery combinations. These are different drugs and goals; a favorable combination is not tested compatibility. Reddit r/BodyHackGuide Community
GH-axis alternatives have different tradeoffs. Preserved comparisons contrast tesa's visceral-fat interest with sermorelin's sleep/longevity framing, longer CJC-with-DAC claims, MK-677 hunger/water talk and direct HGH. Dual-GHRH or HGH layering is debated as redundant; no equivalent dose or safe swap follows. Community
No change is not a reason to guess a larger dose. The two-month nonresponse post contains conflicting microgram/milligram arithmetic. The old record also flags unverified identity, fill and sterility. A poor response could involve expectations, exposure or other factors; it cannot establish underdosing or purity. Reddit r/PeptidePathways Community Community